Spero Therapeutics/ US84833T1034 /
| 6/14/2024 9:57:26 PM | Chg. -0.01 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 1.36USD | -0.37% | 2,252 Turnover: 3,035.17 |
-Bid Size: - | -Ask Size: - | 1.36 | 1.32 |
GlobeNewswire
6/3
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5/16
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire
5/15
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire
5/8
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...
GlobeNewswire
5/1
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
3/13
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Busi...
GlobeNewswire
3/6
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial...
GlobeNewswire
2/28
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infect...
GlobeNewswire
1/31
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
1/2
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipe...
GlobeNewswire
11/21/2023
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possib...
GlobeNewswire
11/13/2023
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
GlobeNewswire
11/6/2023
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Mon...
GlobeNewswire
11/1/2023
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
GlobeNewswire
10/31/2023
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
9/29/2023
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
9/20/2023
Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
GlobeNewswire
9/12/2023
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of ...
GlobeNewswire
9/6/2023
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
9/5/2023
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Sco...
GlobeNewswire
8/31/2023
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
